| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 康为世纪是一家立足于生命科学领域的创新型企业，立足分子检测底层核心技术的自主研发，在酶原料、核酸保存、样本前处理领域有十余年的研发积累，目前，康为世纪累积投资数亿元，总面积超8万余平米，拥有职工600多人，产品达700余种，构建了酶原料、核酸保存、核酸提取纯化、荧光定量PCR、基因测序和核酸质谱6个技术平台，实现了分子检测“核心原料+试剂盒+检测服务”的一体化布局。 康为世纪专长于基因检测试剂的创新，从样本采集与保存，到核酸提取，到分子检测，均实现了自主创新。在医学检测领域，康为世纪旗下拥有多家医学检验所，建立了包括荧光定量PCR、二代测序和核酸质谱在内的多种分子检测技术平台，开发有各类分子检测服务项目一百余项。 未来，康为世纪将秉承推动祖国生命科学事业发展的信念和使命感，秉随“诚信、挚爱、专注、创新”的精神，贯彻“健康有为，合作共赢”的经营理念，持续为全球生命科学研究与应用机构提供创新型的生物产品与服务，为民生健康提供科技保障，让每一个生命健康有为！ | ||||||||||||||||||||||||
| Main Business | 分子检测底层核心技术的自主研发。 | ||||||||||||||||||||||||
| Legal Representative | 王春香 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 戚玉柏 | ||||||||||||||||||||||||
| Solicitors | 上海市通力律师事务所 | ||||||||||||||||||||||||
| Auditors | 大华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0523-86200880 | ||||||||||||||||||||||||
| Fax No | 0523-86200880 | ||||||||||||||||||||||||
| Website | www.cwbio.com | ||||||||||||||||||||||||
| cw688426@cwbio.cn;IRM@cwbio.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 25/10/2022 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.752 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 14.824 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 0.703B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |